PureCycle Technologies Stock (NASDAQ: PCT)

PureCycle Technologies Stock (NASDAQ:PCT), Trade Ideas

PureCycle Technologies

PureCycle Technologies Inc holds a license to commercialize the only patented solvent-based purification recycling technology, developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene (PP) into a virgin-like resin. The proprietary process removes color, odor, and other contaminants from recycled feedstock resulting in virgin-like polypropylene suitable for any PP market.

Long Ideas

News

Small Cap

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

CTRN

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.

Insiders Buying Walgreens And 2 Other Stocks

Penny Stocks

Intraday Update

Movers

ADAP

AFRM

CLSK

CRMT

CVNA

GIFI

GRFS

MARA

PLUG

PRCH

RDFN

RIOT

SNAP

SWBI

UPST

VALN

VTYX

WLDN

U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.

Smith &amp; Wesson Brands Reports Upbeat Earnings, Joins America&#39;s Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday

AFMD

AISP

APEI

BASE

BIAF

BYSI

CERS

CETX

CMAX

CRWD

CXDO

DADA

DAVE

ENCP

FULC

GNPX

HIPO

HSCS

IFBD

INFN

JAGX

LTRN

LYFT

MEDS

MNTS

MSTR

NEPT

NKGN

OCEA

PHUN

ROOT

RVSN

SBFM

SGHC

SOPH

TTEC

UNFI

VINC

XRTX

Shares of  United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

PureCycle Technologies, Inc. - Common stock

PureCycle Technologies Inc

PACT GROUP HLDGS UNSP/ADR by Pact Group Holdings Ltd

Pact Group Holdings Ltd

PCTEL Inc

PCT Ltd

PICTON PPTY INCOME LTD by Picton Ppty Income Ltd.

Paylocity Holding Corporation - Common Stock

Paylocity Holding Corp

BRAVERN VENTURES LTD by Bravern Ventures Ltd

Bravern Ventures Ltd

<p>As you may have heard, cannabis consumption among older folks is on the rise. More specifically, seniors are one of the fastest-growing groups of <a href="https://www.benzinga.com/cannabis">cannabis users in the U.S. </a></p>
<p>As it turns out, many older adults have been consuming weed for decades and new ones are joining in on the fun. Cannabis consumption among our parents and grandparents has quadrupled in the past eight years.</p>
<p>Study after study suggests that older adults are using cannabis to remedy an array of conditions such as sleep issues, pain,&nbsp;inflammation and to activate their appetites. </p>
<p>But most consume because they still enjoy getting high.</p>
<p>"Sure, I sleep better with cannabis and topical creams alleviate my knee pain, but that's all new. I've been smoking pot for the past four decades and I see no reason to stop getting high," said Cynthia P who recently retired as an ER nurse in Ohio where recreational marijuana <a href="https://www.benzinga.com/markets/cannabis/23/11/35664155/ohio-legalizes-cannabis-and-overwhelmingly-approves-abortion-rights">became legal</a> last November.</p>
<p>Scientists and researchers are wisely becoming interested in this Baby Boomer demographic of 77 million, many of whom are healthy, economically stable and have no plans of checking out anytime soon, so they say.</p>
<p>One particular<a href="https://www.frontiersin.org/articles/10.3389/fnagi.2022.804890/full" target="_blank" rel="noreferrer noopener">&nbsp;study</a>,&nbsp;that examined marijuana use in adults aged&nbsp;60 to 88 found that&nbsp;whole-plant cannabis did&nbsp;not harm&nbsp;cognition but rather the opposite.&nbsp;Older cannabis users, relative to non-users, had&nbsp;significantly greater neuronal communication between the cerebellum and hippocampus.</p>
<p><strong>Why?</strong> Age-related changes in the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/22/07/28272841/the-endocannabinoid-system-101-the-basics-made-easy" target="_blank" rel="noreferrer noopener">endocannabinoid system</a>&nbsp;(ECS) include a decrease in the number of cannabinoid receptors throughout the brain.&nbsp;The ECS,&nbsp;a significant aspect of our human physiology that&nbsp;helps maintain homeostasis,&nbsp;is a complex cell-signaling system in the brain and body that interacts with just about all of our&nbsp;other body systems.&nbsp;</p>
<p><strong>Which means? </strong>During normal aging, the decline in cannabinoid receptors correlates with increased levels of inflammation in these brain regions causing a loss of neurons in the hippocampus, which is critical for learning and&nbsp;memory.&nbsp;This, in short, explains age-related memory impairment.&nbsp;&nbsp;</p>
<p>"Oh, I believe that," Cynthia told Benzinga. "While I never consumed for a full shift before going to work, I'm convinced that marijuana has helped keep me and my mind sharp as I aged. I'm not saying it's for everyone, but for people of my generation there's nothing better."</p>
<p><em>Now Read: <a href="https://www.benzinga.com/markets/cannabis/24/04/38341776/hemp-space-grew-3x-the-rate-of-cannabis-where-did-marijuana-get-it-wrong">Hemp Space Grew 3X The Rate Of Cannabis, Where Did Marijuana Get It Wrong?</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Cannabis

Exclusives

It's 4/20, Do You Know Where Your Parents Are?

<p>The Detroit Lions finished with one of their best records in years for the 2023 season, which means they will have a lower pick in the<a href="https://www.benzinga.com/nfldraft/"> 2024 NFL Draft.</a></p>
<p>Would General Manager<strong> Brad Holmes</strong> consider trading out of the first round with the 2024 NFL Draft taking place in Detroit?</p>
<p><strong>What Happened: </strong>Detroit Lions fans might not like the answer given by Holmes to the media on scenarios that could see the Lions trade their 29<sup>th</sup> overall first-round pick and move back in the <a href="https://www.benzinga.com/nfldraft/detroit-live-events/">2024 NFL Draft.</a></p>
<p>Holmes was asked about a scenario of trading out of the first round and didn't hesitate to say he will do what is best for the franchise.</p>
<p>"We have to do the right thing for the organization," Holmes said, as <a href="https://www.detroitlions.com/news/holmes-prepared-to-apologize-to-fans-if-lions-trade-out-of-first-round">reported </a>by Lions writer Mike O'Hara.</p>
<p>Holmes said while he would consider trading out of the first round, it's important to note that, with the draft taking place in Detroit, there might be a greater chance of upsetting the fans if he makes such a move.</p>
<p>A trade out of the first round could mean that any Lions fans in attendance Thursday will have spent all day downtown to watch other teams take their players in the draft.</p>
<p>Holmes said he would send out a "PSA and apologize" if he trades out of the first round.</p>
<p>"Hopefully, our fans will forgive us. We won't expect immediate forgiveness right then and there, but hopefully when the season starts."</p>
<p>Detroit was announced as the host city for the NFL Draft back in 2022.</p>
<p>"Another opportunity for our franchise and our city and just for the world to kind of migrate to downtown Detroit," Holmes said earlier this week.</p>
<p><em>Related Link: <a href="https://www.benzinga.com/general/sports-betting/24/04/38318190/michigan-wolverines-will-have-6-high-demand-players-in-2024-nfl-draft-will-history-repeat-">Michigan Wolverines Will Have 6 High-Demand Players In 2024 NFL Draft: Will History Repeat Itself?</a></em></p>
<p><strong>Why It's Important:</strong> Holmes is no stranger to trading in the NFL Draft. Since joining as the Lions GM in 2021, Holmes has taken part in several drafts for the team and is known for dealmaking.</p>
<p>This includes the 2023 NFL Draft, which saw the Lions trade their sixth overall pick, acquired from the Los Angeles Rams in the <strong>Matthew Stafford</strong> trade. The Lions traded the sixth pick to the Arizona Cardinals and received back the 12<sup>th</sup>, 34<sup>th</sup> and 168<sup>th</sup> overall picks.</p>
<p>Lions fans will remember the 2023 Draft saw several impact players taken including running back <strong>Jahymyr Gibbs </strong>with the 12<sup>th</sup> pick and tight end<strong> Sam LaPorta </strong>with the 34<sup>th</sup> pick. Both rookies played in the 2023 NFL season and were among the top first-year players, finishing third and fourth, respectively, in NFC offensive rookie of the year voting.</p>
<p>The 12-5 record and appearance in the NFC Championship game gives the Lions the 29<sup>th</sup> overall pick, one of their lowest earned in years.</p>
<p>The Lions also have the 61<sup>st</sup> overall pick and 73<sup>rd</sup>, but have only those three picks in the first four rounds, with no fourth-round pick this year. This could prompt Holmes to be open to trades to pick up additional picks. The Lions also have a fifth-round pick, two sixth-round picks and a seventh-round pick, for seven overall picks.</p>
<p>In the 2023 NFL Draft, the Lions had eight picks, including two first-round picks and two second-round picks.</p>
<p>The Lions have had a first round pick in every season since 1994, with 1993 being the last year they didn't select a player in the first round.</p>
<p>The Lions&#8217; top needs by position include cornerback, offensive line and wide receiver. The Lions last took a wide receiver in the first round of 2022 (<strong>Jameson Williams</strong>) and a cornerback in the first round of 2020 (<strong>Jeff Okudah</strong>). For the offensive line, the Lions last took a guard or center in the first round in 2018 with <strong>Frank Ragnow,</strong> and last took an offensive tackle in the first round in 2021 with <strong>Penei Sewell.</strong> Of these four players, three are still with the Lions.</p>
<p>Join Benzinga's live draft reaction show Thursday, April 25 to hear our instant thought on who the Lions take 29<sup>th</sup> overall or our reaction to the Lions trading out of the first round.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; LIVE NFL Draft Watch Party: Benzinga&#039;s Expert Analysis &amp; Reactions!" width="500" height="281" src="https://www.youtube.com/embed/XMBqIWZb7h0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><em>Photo via Shutterstock. </em></p>


Sports

Detroit Lions Have First-Round Pick Every Year Since 1994: Would They Really Trade Out With Draft In Motor City?

<p>&quot;We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints,&quot; said John Brancaccio, Executive Chairman of Hepion. &quot;The Company remains committed to its strategic alternative efforts previously announced in December 2023. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner. There were no safety concerns observed for rencofilstat in the ASCEND-NASH trial.&quot;</p>


Biotech

General

HEPA

Hepion Pharmaceuticals Says Given The Number Of Enrolled NASH Patients To Date And The Low Probability Of Generating Relevant Efficacy Data To Support A Registrational Trial With Our Current Cash Resources, We Have Opted To Wind Down The Program And Assure That Patients Are Transitioned Out Of The Trial In A Safe And Compliant Manner"

Hepion Pharmaceuticals Shares Resumed Trading

<p>Sen.<strong> Elizabeth Warren</strong> (D-Mass.) voiced her support for a Department of Justice antitrust case against leading technology company <strong>Apple Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which was <a href="https://www.benzinga.com/news/24/03/37905532/apple-slams-dangerous-doj-lawsuit-tim-cooks-iphone-suggestion-returns-to-haunt-and-potential-google">announced last month.</a></p>
<p>In comments shared on social media, Warren took aim at the smartphone market segment of Apple.</p>
<p><strong>What Happened:</strong> Apple is one of the largest smartphone companies in the world and in 2023 had seven of the top 10 selling smartphones globally <a href="https://www.benzinga.com/news/24/02/37245799/apple-dominates-2023-smartphone-list-with-7-of-top-10-models-why-its-important-for-iphone-growth">according to a report.</a></p>
<p>According to Warren, Apple has a monopoly in the smartphone market and one of the company's key features could be ruining friendships and relationships.</p>
<p>"Green texts on iPhones, they're ruining relationships," Warren <a href="https://twitter.com/SenWarren/status/1781086997014040759">said </a>in a video posted on X.</p>
<p>The green texts refer to the texts that come from non-Apple phones in green bubbles versus the blue bubbles displayed by iPhone users.</p>
<p>"Non iPhone users everywhere are being excluded from group texts."</p>
<p>Warren said that this means some non-Apple smartphone users are not being included in chats about vacation plans, group chats or chats with other sports fans.</p>
<p>"And who's to blame here? Apple."</p>
<p>Warren said that the green vs. blue bubble text icons are just one example of the dirty tactics used by Apple to "keep a stranglehold on the smartphone market."</p>
<p>"Apple has used its monopoly on the smartphone to lock Americans into services and amass billions of dollars in profits."</p>
<p>Warren mentioned that apps that would let Google users use iMessage and get blue texts were <a href="https://www.benzinga.com/news/23/12/36165068/apple-pulls-plug-on-imessage-for-android-app-beeper-mini-its-back-to-green-bubbles-now-for-android-u">blocked by Apple.</a></p>
<p>"It's time to break up Apple's monopoly now."</p>
<p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37876155/apple-doj-lawsuit-could-challenge-core-business-model-leading-analyst-predicts-what">Apple DOJ Lawsuit Could Challenge &#8216;Core Business Model&#8217;: Leading Analyst Predicts What&#8217;s Next For Tech Giant</a></em></p>
<p><strong>Why It's Important</strong>: The video shared by Warren was Community Noted on X, with readers providing more context.</p>
<p>"As of Jan 2024, iPhone has a 57% market share, to Android 42% in North America. A monopoly is exclusive control, or no close substitutes," the note reads.</p>
<p>In March, the Department of Justice filed an antitrust suit against Apple, which includes allegations that the company restricts access to iPhone hardware and software features.</p>
<p>A <a href="https://9to5mac.com/2024/04/19/elizabeth-warren-on-green-texts/">report </a>from 9to5Mac indicates that the antitrust lawsuit now encompasses claims from non-iPhone users who feel socially stigmatized and excluded in chats with iPhone users. This issue stems from the ongoing<a href="https://www.benzinga.com/news/23/09/34818276/get-the-message-google-roasts-apple-with-new-mocking-ipager-add-to-end-green-vs-blue-text-bubbles-wa"> blue vs. green bubble text debate.</a></p>
<p><strong>AAPL Price Action</strong>: Apple shares closed at $165.00 on Friday, versus a 52-week trading range of $162.80 to $199.62.</p>
<p><em>Read Next:<a href="https://www.benzinga.com/general/politics/24/04/38305131/elizabeth-warren-says-trump-had-only-2-accomplishments-as-president-huge-difference-between-bide"> Elizabeth Warren Says Trump Had Only 2 Accomplishments As President: &#8216;Huge Difference Between&#8217; Biden, Trump</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Politics

Legal

AAPL

Elizabeth Warren Attacks Apple Smartphone 'Monopoly': 'Green Texts On iPhones, They're Ruining Relationships'

Trading Halt: Halt status updated at 4:55:00 PM ET: Quotation Resumption: News and Resumption Times

Management

AFJK

On April 15, Aimei Health Technology's Juan Fernandez Pascual Tendered His Resignation As CEO, Secretary And A Director; Co Appointed Junheng Xie As CEO, Secretary And A Director

Global

Honda Exec Says Company To Invest 4.2B Reais In Brazil Plant, Focusing On Hybrid-Flex Vehicles

COSM

Cosmos Health Received Nasdaq Notice On Late Filing Of Its Form 10-K; On April 17 Received Notification Letter Stating Co Is No Longer In Compliance With Nasdaq Listing Rule 5250(c)(1); Intends To Resolve Deficiency And Regain Compliance With Nasdaq Listing Rules

BTOG

On Feb 19, Bit Origin Ltd Terminated Employment Of Its CFO, Xia Wang; On April 10, Lucas Wang Resigned As CEO And Chairman Of Board; Current COO, Has Been Appointed CEO, Chairman Of Board And A Director Of Co; Co To Conduct A Search To Replace Xia Wang As Company's CFO

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>ServiceNow</strong>.</p>
<p>Looking at options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) we detected 56 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 64% with bearish.</p>
<p>From the overall spotted trades, 25 are puts, for a total amount of $1,473,153 and 31, calls, for a total amount of $2,469,435.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $1040.0 for ServiceNow over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $300.0 to $1040.0 in the last 30 days. </p>
<h3>ServiceNow Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559550_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$108.8</td>
<td>$106.7</td>
<td>$108.8</td>
<td>$700.00</td>
<td>$598.4K</td>
<td style="text-align: right;">142</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$31.7</td>
<td>$36.5</td>
<td>$500.00</td>
<td>$310.2K</td>
<td style="text-align: right;">35</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$39.1</td>
<td>$36.7</td>
<td>$39.1</td>
<td>$700.00</td>
<td>$293.2K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$32.8</td>
<td>$32.1</td>
<td>$32.1</td>
<td>$720.00</td>
<td>$227.9K</td>
<td style="text-align: right;">75</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$33.0</td>
<td>$31.9</td>
<td>$33.0</td>
<td>$800.00</td>
<td>$132.0K</td>
<td style="text-align: right;">131</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<h3>Current Position of ServiceNow</h3>
<ul>
<li>Trading volume stands at 1,536,830, with NOW's price down by -2.39%, positioned at $713.91.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

This Is What Whales Are Betting On ServiceNow

<p>Financial giants have made a conspicuous bearish move on AstraZeneca. Our analysis of options history for AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 16% of traders were bullish, while 83% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $90,336, and 9 were calls, valued at $981,928.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $66.0 and $77.5 for AstraZeneca, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for AstraZeneca's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AstraZeneca's whale activity within a strike price range from $66.0 to $77.5 in the last 30 days. </p>
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559545_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.06</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$67.50</td>
<td>$594.6K</td>
<td>14.1K</td>
<td>8.2K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.65</td>
<td>$1.54</td>
<td>$1.55</td>
<td>$67.00</td>
<td>$69.4K</td>
<td>2.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.52</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$67.00</td>
<td>$67.6K</td>
<td>2.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$1.49</td>
<td>$1.25</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$66.7K</td>
<td>2.5K</td>
<td>24</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.57</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$49.6K</td>
<td>2.5K</td>
<td>920</td>
</tr>
</tbody>
</table>
</p>
<h3>About AstraZeneca</h3>
<p>A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.</p>
<p>Following our analysis of the options activities associated with AstraZeneca, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is AstraZeneca Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,720,283, the price of AZN is up by 0.28%, reaching $68.55.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AstraZeneca options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Looking At AstraZeneca's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Astera Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for <strong>Astera Labs</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $55,500, and 8, calls, for a total amount of $413,781.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Astera Labs during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Astera Labs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale trades within a strike price range from $35.0 to $100.0 in the last 30 days. </p>
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559539_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$50.00</td>
<td>$73.5K</td>
<td style="text-align: right;">43</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.7</td>
<td>$30.9</td>
<td>$32.52</td>
<td>$35.00</td>
<td>$65.0K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$65.00</td>
<td>$63.8K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">89</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$6.1</td>
<td>$5.6</td>
<td>$5.9</td>
<td>$65.00</td>
<td>$59.0K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">472</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$11.1</td>
<td>$10.7</td>
<td>$11.1</td>
<td>$75.00</td>
<td>$55.5K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>
</p>
<h3>About Astera Labs</h3>
<p>Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.</p>
<p>Having examined the options trading patterns of Astera Labs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Astera Labs</h3>
<ul>
<li>Trading volume stands at 3,996,863, with ALAB's price down by -10.18%, positioned at $63.7.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Astera Labs</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $88.0.</p>
<ul>
<li>Reflecting concerns, an analyst from Evercore ISI Group lowers its rating to Outperform with a new price target of $100.</li>
<li>An analyst from Barclays downgraded its action to Overweight with a price target of $85. </li>
<li>Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $85.</li>
<li>In a cautious move, an analyst from JP Morgan downgraded its rating to Overweight, setting a price target of $85. </li>
<li>Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $85.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Astera Labs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ALAB

Decoding Astera Labs's Options Activity: What's the Big Picture?

GILD

LPTX

Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024

Offerings

KZIA

Kazia Therapeutics Ltd Entered Into Purchase Agreement With Alumni Capital LP; Pursuant To Purchase Agreement, May Sell To Alumni Capital Up To $15M Of American Depositary Shares From Time To Time

Momentus Inc Receives Nasdaq Deficiency Notification Regarding Delayed Form 10-K

<p>Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Form 10-K"), with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires the timely filing of all required periodic reports with the SEC.<br /><br />&nbsp;</p>
<p>The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Under the Nasdaq rules, the Company has 60 calendar days, or until June 17, 2024, to file the 2023 Form 10-K or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If the Company submits a plan to Nasdaq and Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the filing's due date, or until October 14, 2024, to regain compliance. If the Company fails to timely regain compliance with Nasdaq Listing Rule 5250(c)(1), the Company's common stock will be subject to delisting from Nasdaq.</p>
<p>The Company continues to work diligently to complete the 2023 Form 10-K and currently intends to file the 2023 Form 10-K by no later than June 10, 2024.</p>
<p>This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.</p>


GURE

Gulf Resources Announces Receipt Of Nasdaq Non-Compliance Notice Notifying The Company That Due To The Co's Failure To Timely File Its Annual Report On Form 10-K For The Fiscal Year Ended December 31, 2023

<p>Lifecore Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) (the "Company") announced today that, on April 15, 2024, the Company received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the "Q3 Form 10-Q") and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the "Q1 Form 10-Q" and "Q2 Form 10-Q," respectively, and together with the Q3 Form 10-Q, the "Filings") with the Securities and Exchange Commission (the "SEC"), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company's continued listing on Nasdaq Global Select Market.<br /><br />&nbsp;</p>
<p>The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Select Market. As previously disclosed, Nasdaq had previously granted the Company until February 12, 2024 to regain compliance with the Listing Rule, and, on February 13, 2024, the Company received the Staff Delisting Determination notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company's securities from Nasdaq as a result of the Company not being in compliance with the Listing Rule. The Company appealed the Staff Delisting Determination, and, on April 16, 2024, the Company appeared for the hearing in which the Company requested a further stay of any suspension or delisting action to enable the Company to regain compliance with the Listing Rule. The Nasdaq Hearings Panel has not yet issued its decision, although the Company anticipates that a decision will be forthcoming.</p>
<p>The Company continues to work diligently to complete the Filings and intends to file the Filings as promptly as possible to regain compliance under the Listing Rule. However, there can be no assurance that such periodic reports will be filed before the expiration of any stay granted by Nasdaq, or that the Nasdaq Hearing Panel will grant the Company's request for a further stay of any suspension or delisting action</p>
<p>This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.</p>


LFCR

Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report For The Fiscal Quarter Ended February 25, 2024 And Its Continued Delay In Filing Its Quarterly Report On Form 10-Q For The Quarterly Periods Ended August 27, 2023 And November 29, 2023

<p>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>), a global subsea mineral exploration and validation company, reported that on April 17, 2024, Odyssey received a notice from Nasdaq Regulation that Odyssey is not in compliance with Nasdaq Rule 5250(c)(1) because it had not yet filed its Form 10-K for the period ended December 31, 2023 (the "Form 10-K") with the Securities and Exchange Commission (SEC). Odyssey plans to regain compliance with Nasdaq Rule 5250(c)(1) by filing the Form 10-K with the SEC, which it expects to do as soon as practicable.</p>


OMEX

Odyssey Marine Exploration Addresses NASDAQ Compliance Matters; Plans To Regain Compliance With Nasdaq Rule 5250(c)(1) By Filing The Form 10-K With The SEC, Which It Expects To Do As Soon As Practicable

<p>Intelligent Living Application Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) ("Intelligent Living" or the "Company"), a premium lockset manufacturer in Hong Kong, announced today that, on April 17, 2024, the Company received a written notification from the NASDAQ Stock Market Listing Qualifications Staff (the "Staff") indicating that the Company has been granted an additional 180 calendar day period or until October 14, 2024, to regain compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to NASDAQ Listing Rule (the "Minimum Bid Price Requirement").</p>
<p>NASDAQ's determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the NASDAQ Capital Market, with the exception of the bid price requirement, and the Company's written notice to NASDAQ of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company's security is at least $1.00 per share for a minimum of 10 consecutive business days, NASDAQ will provide written confirmation of compliance and this matter will be closed. If compliance cannot be demonstrated by October 14, 2024, Staff will provide written notification that the Company's securities will be delisted. At that time, the Company may appeal the Staff's determination to a Hearings Panel (the "Panel") of NASDAQ.</p>
<p>This notification from Nasdaq has no immediate effect on the listing or trading of the Company's ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol "ILAG".&nbsp; The Company will monitor the closing bid price of its ordinary shares and will consider various options to regain compliance before October 14, 2024.</p>


ILAG

Intelligent Living Application Group Inc. Granted Extension Indicating That The Co Has Been Granted An Additional 180 Day Or Until October 14, 2024, To Regain Compliance With The $1.00 Minimum Closing Bid Price Requirement To Meet Nasdaq Minimum Bid Price Requirement

Craig-Hallum analyst Eric Stine maintained a Hold rating on PureCycle Technologies (PCT – Research Report) today. The company's shares closed yeste...

Craig-Hallum Keeps Their Hold Rating on PureCycle Technologies (PCT)

Overall market sentiment has been neutral on Purecycle Technologies Inc (PCT)  stock lately. PCT receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator. Purecycle Technologies Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on PCT!See Full PCT Repor

Is it Time to Dump Purecycle Technologies Inc (PCT) Stock After it Has Risen 2.40% in a Week?

Purecycle Technologies Inc (PCT) is near the bottom in its sector according to InvestorsObserver.PCT gets an overall rating of 31. That means it scores higher than 31% of stocks.Purecycle Technologies Inc gets a 27 rank in the Industrials sector. Industrials is number 1 out of 11 sectors. PCT has an Overall Score of 31. Fi

Is Purecycle Technologies Inc (PCT) Stock a Good Value Friday?

Purecycle Technologies Inc (PCT) stock has risen 13.29% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives PCT stock a score of  34 out of a possible 100. That rank is  influenced by a short-term technical score of 32. PCT's rank also in

Should You Buy Purecycle Technologies Inc (PCT) Stock Thursday?

A rating of 25 puts Purecycle Technologies Inc (PCT) near the top of the Industrials sector according to InvestorsObserver.Purecycle Technologies Inc's score of 25 means that it ranks higher than 25% of stocks in the sector. In addition, its overall score of 25 ranks it higher than 25% of all stocks. PCT has an Overall Sco

Will Purecycle Technologies Inc (PCT) Stay at the Bottom of the Industrials Sector?

Warning: PCT is at high risk of performing badly

The market has been down on Purecycle Technologies Inc (PCT)  stock recently. PCT gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Purecycle Technologies Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PCT!See Full PCT ReportWhat is Stock Senti

Should You Buy Purecycle Technologies Inc (PCT) Stock on Wednesday?

PureCycle schedules operational pause at Ironton Purification Facility from April

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>There are some <a href="https://investorplace.com/industries/industrial/">industrial stocks</a> that short sellers are targeting heavily in April this year. Short sellers often target stocks they perceive to be overvalued or companies facing significant challenges or headwinds. By short selling, they stand to profit if the stock price drops as they can buy back the borrowed shares at a lower cost than what they sold them for initially. Thus, a high short interest can be both a warning sign and an opportunity, depending if you own or want to sell shares.</p>



<p>The industrial sector can be ripe for short sellers due to the cyclical nature of the sector. When the economy is going strong, these companies do well, and vice-versa. The issue arises when the market turns pessimistic, which can turn slight weaknesses of companies into reasons to dump the stock. Shorts can also target companies for other reasons, including poor fundamentals, high debt load or a bleak outlook for future performance, among others.</p>



<p>So here are three industrial stocks that short sellers are targeting heavily.</p>



<h2>Purecycle Technologies (PCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/01/recycle-1600-300x169.png" alt="Bins are filled with various recyclibles, including cardboard, glass, and plastic"><div>Source: Rawpixel.com / Shutterstock</div></div><p><strong>Purecycle Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pct-stock-quote/"><strong>PCT</strong></a>) is focused on recycling polypropylene into virgin-like resin. The environmental services and equipment company has attracted short sellers, possibly due to doubts about its technology&rsquo;s scalability or environmental impact.</p>



<p>Aside from these broader issues, <a href="https://ca.finance.yahoo.com/news/scheduled-operational-pause-ironton-purification-204500635.html">PCT has undergone an &ldquo;operational pause&rdquo;</a> this week with the CEO stating, &ldquo;This pause will allow us to make improvements to our flagship facility based off what we learned during operations over the last three months. It&rsquo;s those improvements that should help take us into the next phase of production.&rdquo;</p>



<p>PCT <a href="https://stockanalysis.com/stocks/pct/statistics/">is currently pre-revenue</a>, and 43.12% of its total share float has been sold short at the time of writing. There are other cracks in PCT&rsquo;s fundamentals. They include a high debt load and a net cash position of &mdash; $396.48 million or &mdash; $2.41 per share.</p>



<p>Troublingly, it burnt through $248.81 million within the last 12 months. It needs to double its cash and cash equivalents of $147.33 to stay solvent. Otherwise, it must either dilute shareholders to add to its growing pile of debt.&nbsp;</p>



<h2>Enovix (ENVX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/11/ev-batteries-mmat1600-300x169.png" alt="Electric car lithium battery pack and power connections. MMAT stock. Battery Stocks"><div>Source: asharkyu / Shutterstock.com</div></div><p><strong>Enovix</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/envx-stock-quote/"><strong>ENVX</strong></a>) specializes in the development and manufacture of advanced lithium-ion batteries. At the time of this writing, around 27.18% of its total float is being sold short.</p>



<p>In 2023, ENVX <a href="https://stockanalysis.com/stocks/envx/statistics/">reported a significant year-over-year revenue increase</a>, reaching $7.4 million in the fourth quarter, up from $1.1 million in Q4 2022. Despite this revenue growth, the company experienced a net loss of $59.98 million in Q4, reflecting the costs associated with scaling operations.</p>



<p>For 2024, ENVX projects Q1 revenue to be between $3.5 million and $4.5 million, with an adjusted EBITDA loss of $24 million to $31 million.&nbsp;</p>



<p>Some concerns are brewing on the horizon for ENVX in terms of its financials. For one, it already has over 150 million shares outstanding. This may be an issue, as it has only around two years of cash and equivalents on its balance sheet if it maintains its same level of cash burn. Additionally, share dilution is possible, or it could add to its debt pile of $117 million.</p>



<h2>Zynex (ZYXI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div><p><strong>Zynex</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/zyxi-stock-quote/"><strong>ZYXI</strong></a>) is an advanced medical equipment and technology company known for developing noninvasive devices for pain management and rehabilitation.</p>



<p>ZYXI <a href="https://zynexmed.investorroom.com/2024-02-29-Zynex-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results">reported significant growth</a> in its 2023 fiscal year, achieving a 17% increase in revenue to $184.3 million. For 2024, ZYXI has set ambitious targets, aiming for approximately 23% growth in total revenue, reaching around $227 million.</p>



<p>Manufacturers like ZYXI are considered industrials since they experience boom and bust cycles like the wider economy. Like others on this list, the <a href="https://stockanalysis.com/stocks/zyxi/statistics/">prospects for ZYXI are bleak</a>, according to the bears. They have sold 36.67% of its float short.</p>



<p>It should be noted that this reduction of <a href="https://www.defenseworld.net/2024/04/01/denali-advisors-llc-sells-42700-shares-of-zynex-inc-nasdaqzyxi.html">shares coincided with a reduction</a> of one of its investor&rsquo;s holdings on Apr. 1. This may very well be coincidental.</p>



<p>Regardless, ZYXI&rsquo;s issue could come from shares of it being overvalued. Its P/E ratio for instance, is 46 times earnings. It also had $18 million in EBITDA from $184 million in revenue over the last 12 months. The market could surmise that its valuation must come back down to earth. The company&rsquo;s stock price has increased around 15% year to date.</p>



<p><em>On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> </em>InvestorPlace.com Publishing Guidelines</a>.</p>
<div><p>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/3-industrial-stocks-short-sellers-are-hammering-cracks-in-the-foundation/">3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on PureCycle Technologies (PCT – Research Report) and American...

Analysts Offer Insights on Industrial Goods Companies: PureCycle Technologies (PCT) and American Superconductor (AMSC)

AMSC

ENVX

ZYXI

Press Releases

PureCycle Resumes Pellet Production at Ironton Purification Facility

PureCycle Provides Ironton Operations Update

Innventure LLC and Learn CW Investment Corporation Announce Filing of Registration Statement on Form S-4 in Connection With Proposed Business Combination

PureCycle Provides Notice of Agreement in Principle to Purchase Ironton Bonds

PureCycle Schedules Fourth Quarter 2023 Corporate Update

PureCycle Appoints Jaime Vasquez as Chief Financial Officer

PureCycle Reschedules Fourth Quarter 2023 Corporate Update to March 6

PureCycle Technologies Fourth Quarter and Fiscal Year Ending 2023 Update

PureCycle Resin Used by Churchill Container to Produce Souvenir Cups

Scheduled Operational Pause at Ironton Purification Facility to Begin in April

AdvanSix

Braskem

Cabot

Core Molding Technologies Inc Common Stock

Core Molding Technologies

CN Energy Group Inc. - Class A Ordinary Shares

CN Energy Group

Crown Electrokinetics Corp. - Common Stock

Crown ElectroKinetics

Gulf Resources

Hawkins

Koppers Hldgs

Kronos Worldwide

Loop Industries

Mativ Holdings

Orion

Olin

Origin Materials, Inc. - Class A Common Stock

Origin Mat

Tantech Hldgs

Tronox Holdings

Trinseo

Westlake

Westlake Chemical Partners LP Common Units representing limited partner interests

Westlake Chemical